Summary：Elicio Therapeutics Soars as Russell 2000 and 3000 Indexes New AdditionBOSTON, June 29, 2026 (GLOBE

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

Elicio Therapeutics Soars as Russell 2000 and 3000 Indexes New Addition

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company pioneering innovative immunotherapies for KRAS-driven cancers, has made a significant stride in its journey, with its recent inclusion in the prestigious Russell 2000 and 3000 indexes. This development has sparked a surge in the company's stock, underscoring the market's enthusiasm for its potential.

The addition to these indexes, which are widely tracked by investors and fund managers, is a testament to Elicio's growing market presence and its increasing relevance in the biotechnology sector. As a result of this inclusion, Elicio's stock has witnessed a notable uptick, reflecting the confidence investors have in the company's prospects. The Russell indexes are considered a benchmark for small-cap and broad-market performance, and being part of them can significantly enhance a company's visibility and attractiveness to a wider investor base.

Industry analysts view Elicio's inclusion in the Russell indexes as a positive indicator for the company's future performance. With a focus on developing next-generation immunotherapies for KRAS-driven cancers, Elicio is at the forefront of a rapidly evolving field. KRAS mutations are among the most common genetic alterations found in various cancers, and the development of effective treatments targeting these mutations has been a long-standing challenge. Elicio's innovative approach has the potential to address this unmet medical need, offering new hope to patients and driving growth for the company.

As Elicio continues on its growth trajectory, the market is likely to remain keenly interested in its progress. The company's inclusion in the Russell 2000 and 3000 indexes is expected to provide a boost to its stock liquidity and potentially attract more institutional investors. With its cutting-edge technology and a strong pipeline, Elicio is well-positioned to make significant advancements in the field of immunotherapy.

In conclusion, Elicio Therapeutics' addition to the Russell 2000 and 3000 indexes marks a significant milestone for the company. As it continues to develop its innovative immunotherapies, the market is likely to watch its progress closely. With its strong potential for growth and its commitment to addressing a critical medical need, Elicio is poised to make a lasting impact in the biotechnology sector.